About Illumina Ventures
Illumina Ventures is a venture capital firm founded in 2016. It is primarily based out of Foster City, United States. As of Sep 2026, Illumina Ventures is an active investor, having invested in 57 companies, with 4 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series A round of Robigo Overall, Illumina Ventures portfolio has seen 1 unicorn, 4 IPOs and 12 acquisitions including key companies like CareDx, Twist Bioscience and Attovia. A lot of funds co-invest with Illumina Ventures, with names like Arch Venture Partners sharing a substantial percentage of its portfolio. Illumina Ventures has team of 15 people including 4 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 4 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
Portfolio Soonicorns
Illumina Ventures' List of Top Investments
Illumina Ventures has a portfolio of 57 companies, one of which is a Unicorn. Their most notable investments are in SQZBiotech and Arima Genomics.Their portfolio spans across United States, United Kingdom, France and 4 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 5 other sectors, across stages such as Series A, Series B and 4 more. Here is the list of top investments by Illumina Ventures:
Provider of precision medicine, preventative health assessments, and longevity care. The company offers comprehensive health assessments to detect life-threatening conditions early. It focuses on data-driven, personalized healthcare designed to uncover health risks. The company provides services to help individuals take control of their health.
Key facts about Human Longevity
2. CareDx
Developer of medical solutions for transplant patients. It has developed precision medicine solutions that offer products, testing services, and digital healthcare solutions along with the pre-and post-transplant patient journey. It provides AlloSure products for a kidney transplant. It is a non-invasive donor-derived cell-free DNA test for identifying kidney injury. It can determine active rejection, enabling better management of your kidney transplant patients. Other products include heart transplants, lab products, remotrac, and others.
Key facts about CareDx
- Founded Year: 1998
- Location: Brisbane (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $138M
- Employee Count: 862 as on Aug 31, 2026
- Investors: Intel, Integral Capital Partners and 24 Others
- Latest Funding Round: Conventional Debt, Mar 01, 2018, $*****
- Highlight: Public
Developer of a semiconductor-based DNA synthesis platform. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA which is used in diverse fields of medicine, agriculture, industrial chemicals and data storage. It offers synthetic genes, oligo pools, and NGS target enrichment to support research and innovation
Key facts about Twist Bioscience
- Founded Year: 2013
- Location: San Francisco (United States)
- Annual Revenue: $100M - $500M as on Sep 30, 2025
- Stage: Public
- Total Funding till date: $321M
- Employee Count: 1,308 as on Aug 31, 2026
- Investors: Foresite Capital, Fidelity Investments and 39 Others
- Latest Funding Round: Series F, Apr 02, 2018, $*****
- Highlight: Public
4. Attovia
Developer of antibody-based therapeutics for immune-mediated diseases and oncology. The company leverages ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement. It develops a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology.
Key facts about Attovia
- Founded Year: 2023
- Location: Fremont (United States)
- Stage: Public
- Total Funding till date: $255M
- Employee Count: 52 as on Aug 31, 2026
- Investors: Marshall Wace, Frazier Life Sciences and 13 Others
- Latest Funding Round: Series C, Apr 15, 2025, $*****
- Highlight: Public
Provider of solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. The company's proprietary NULISA Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. Applications include clinical assay development, biomarker discovery and validation, and drug development.
Key facts about Alamar Biosciences
- Founded Year: 2018
- Location: Fremont (United States)
- Stage: Public
- Total Funding till date: $250M
- Employee Count: 242 as on Aug 31, 2026
- Investors: T. Rowe Price, Sands Capital and 7 Others
- Latest Funding Round: Series C, Jan 12, 2026, $*****
- Highlight: Public
Illumina Ventures' Year-on-Year Investment Trends
Illumina Ventures has invested in 57 companies over the last 10 years, with an average of 4 new investments annually in the last 10 years. In 2025, it made 5 investments, while as of Sep 2026, it has made 8 investments in this year. Its most recent first time investment was in Robigo and most recent follow-on round was in Encoded.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 4 | 4 | 8 |
2025 | 2 | 3 | 5 |
2024 | 5 | 1 | 6 |
2023 | 4 | 2 | 6 |
2022 | 3 | 1 | 4 |
2021 | 5 | 6 | 11 |
2020 | 5 | 6 | 11 |
2019 | 2 | 2 | 4 |
2018 | 6 | 2 | 8 |
2017 | 5 | 0 | 5 |
Illumina Ventures' Investments by Stage
Illumina Ventures is primarily an Early Stage Investor investor majorly investing in Series A (22) rounds where average round size is $483M, Series B (13) rounds where average round size is $960M and Series C (4) rounds where average round size is $269M.Stage of entry | No. of Investments |
|---|---|
Series A | 22 |
Series B | 13 |
Series C | 4 |
Seed | 2 |
Series D | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Illumina Ventures' Investments by Sector
Illumina Ventures has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, HealthTech and Sustainability Tech. Notably, it has invested in 54 Tech companies, 53 Enterprise (B2B) companies, 11 Software companies and at least 8 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 37 |
High Tech | 26 |
Enterprise Applications | 7 |
HealthTech | 4 |
Sustainability Tech | 4 |
Others | 9 |
Note: We have considered here, only first round of investments
Illumina Ventures' Investments by Geography
Illumina Ventures has made most investments in United States (36), followed by United Kingdom where it has made 3 investments.Country | No. of Investments |
|---|---|
United States | 36 |
United Kingdom | 3 |
France | 2 |
Ireland | 1 |
Note: We have considered here, only first round of investments
Illumina Ventures' recent investments
Illumina Ventures has made 8 investments in 2026 so far. Robigo and Encoded are the latest among them.Here are the most recent investments by Illumina Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 18, 2026 | United States | Series A | 9126 | [+3] | |
Sep 09, 2026 | United States | Series F | 1264 | [+10] | |
Jun 22, 2026 | United States | Series A | 9616 | ||
Jun 21, 2026 | United States | Series A | 2655 | ||
Jun 08, 2026 | United States | Series B | 9898 | [+14] |
Unicorns in Illumina Ventures' Portfolio
Illumina Ventures has 1 unicorn in its portfolio - LetsGetChecked. The most recent unicorn in their portfolio is LetsGetChecked which became a unicorn in 2021, 1 years after Illumina Ventures first invested in it.Here is a list of unicorns in Illumina Ventures' portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
65 | Online platform to order at home diagnostic tests for all health conditions | 2013 | Dublin | Series D | gumchzw |
IPOs and Publicly Listed companies in Illumina Ventures' Portfolio
4 of Illumina Ventures' portfolio companies have become public. Attovia got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Aug 2026 at marketcap of $731M and Alamar Biosciences got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $1.14B.Here are Illumina Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 05, 2026 | May 09, 2024 | Series B | 5182 | |
Apr 17, 2026 | Sep 08, 2021 | Series B | 8694 | |
Oct 31, 2018 | Jan 19, 2016 | Series D | 9671 | |
Jul 17, 2014 | - | - | 8904 |
Acquired companies in Illumina Ventures' Portfolio
12 companies from Illumina Ventures' portfolio have been acquired. The most recent acquisition was Stilla Technologies in Feb 2025 by Bio Rad for $*****.Here are Illumina Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 14, 2025 | Nov 20, 2018 | Series A | 9308 | |
Dec 19, 2024 | Mar 08, 2022 | Series B | 2108 | |
Jul 09, 2024 | 2020 | Series A | 8373 | |
Feb 29, 2024 | Aug 08, 2018 | Series C | 2706 | |
Oct 22, 2021 | Mar 21, 2018 | Series B | 2295 |
Team profile of Illumina Ventures
Illumina Ventures has a team of 15 members including 4 Partners and 2 Principals located in United States. Illumina Ventures' team does not sit on the board of any company as of now.Here is a list of top team members in Illumina Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Tucson | - | ||
Partner | San Jose | - | ||
Partner | United States | - | ||
Partner | Chevy Chase | - | ||
Principal | San Diego | - | - | |
Principal | Oakland | - |
Co-investors of Illumina Ventures
Over the past 10 years, 412 investors have co-invested in Illumina Ventures's portfolio companies. This includes funds and angels.
- Invested before Illumina Ventures: HHS, Illumina and 100 others have invested in rounds before Illumina Ventures. There are 9 companies where HHS has invested before Illumina Ventures and 5 companies where Illumina has invested before Illumina Ventures.
- Top Co-investors of Illumina Ventures: 178 investors entered a company along with Illumina Ventures. These include investors like Arch Venture Partners (6 companies).
- Invested after Illumina Ventures: A total of 132 investors have invested in Illumina Ventures's portfolio after their investments. Top Investors include Casdin Capital (6 companies), Alexandria (3 companies) and Vida Ventures (2 companies).
Recent News related to Illumina Ventures
•
Robigo and Leaps by Bayer Announce Series A FinancingFinancial Times•Sep 17, 2026•Robigo, Leaps by Bayer, Illumina Ventures
•
SonoThera raises $125M for non-viral gene therapy approachEndpoints•Jun 10, 2026•SonoThera, Medical Excellence Capital, UCB Ventures, Leaps by Bayer and 10 others
•
Lightcast Raises $27 Million to Push Functional Single-Cell Analysis Toward the Lab BenchTechnologies.org•Apr 15, 2026•Lightcast, Arch Venture Partners, ND Capital, OMX Ventures and 3 others
•
Alamar Biosciences Announces Oversubscribed Convertible Note Financing and Expansion of Leadership TeamPR Newswire•Jan 12, 2026•Braidwell, Alamar Biosciences, T. Rowe Price, Sands Capital and 3 others
•
Latham Advises erad on US$33 Million Debt FinancingLegal Desire•Nov 14, 2025•Stride Ventures, Latham & Watkins, Erad, AMR Action Fund and 2 others
•
•
Hepta Unveils First Multi-Omic Atlas of MASH, Linking Liver Pathway Biology to cfDNA Methylation in BloodBusiness Wire•Nov 10, 2025•Hepta Bio Solutions, SeaX Ventures, AME Cloud Ventures, Alumni Ventures and 2 others
•
Hepta Bio raises $6.7M to spot liver disease, adapting DNA technology from cancer and prenatal screening.Endpoints•Nov 05, 2025•GRAIL, Illumina, Hepta Bio Solutions, SeaX Ventures and 4 others
•
Predicta Biosciences Raises $23.4M in Series A FundingFinSMEs•Oct 02, 2025•BrightEdge, Predicta Biosciences, Mass General Brigham, Engine Ventures and 5 others
•
NuCicer Secures $11.5M to Expand High-Protein Chickpeas and Advance Predictive Breeding PlatformNewswire•Jul 30, 2025•NuCicer, Bayer, Illumina Ventures, Better Ventures and 3 others
